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Background: Reagent strip testing for microhaematuria has long been used for community diagnosis of Schistosoma
haematobium. Sensitivities and specificities are reasonable, and hence, microhaematuria can serve as a proxy
for S. haematobium infection. However, assessment of test performance in the context of the underlying
S. haematobium prevalence is rare and test parameters other than sensitivity and specificity have been neglected.
Methods: Data about the association between microhaematuria and urine filtration results from three studies were
compared and put into context with findings from a recent Cochrane review. Data were stratified by S. haematobium
prevalence to identify prevalence-related differences in test performance. Kappa agreement and regression models were
employed to compare data for different S. haematobium prevalence categories.
Results: We found a “background” prevalence of microhaematuria (13 %, on average) which does not seem to be
associated with schistosomiasis in most settings, irrespective of the prevalence of S. haematobium. This background level
of microhaematuria might be due to cases missed with urine filtration, or alternative causes apart from S. haematobium.
Especially in very-low prevalence settings, positive results for microhaematuria likely give an inaccurate picture of the
extent of S. haematobium, whereas negative results are a sound indicator for the absence of infection.
Conclusions: Reagent strip testing for microhaematuria remains a good proxy for urogenital schistosomiasis, but
implications of test results and scope of application differ depending on the setting in which reagent strips are employed.
In very-low prevalence settings, microhaematuria is an unstable proxy for urogenital schistosomiasis and treatment
decision should not be based on reagent strip test results alone. Our findings underscore the need for highly accurate
diagnostic tools for settings targeted for elimination of urogenital schistosomiasis.
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SchistosomiasisBackground
Since the early 1980s, reagent strip testing for microhae-
maturia has been used as an indirect diagnostic assay for
Schistosoma haematobium [1, 2]. Indeed, various studies
validated reagent strips against standard urine filtration
and concluded that the detection of microhaematuria is
a valid proxy for urogenital schistosomiasis and related* Correspondence: juerg.utzinger@unibas.ch
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(http://creativecommons.org/publicdomain/zemorbidity [3–6]. In a recent Cochrane systematic re-
view it has been summarised that reagent strip testing
for S. haematobium diagnosis has an overall sensitivity
and specificity of 75 % and 87 %, respectively [4]. For
specific settings it was suggested that reagent strip
testing can be used for individual diagnosis and treat-
ment decision [1, 7, 8], while other groups described
reagent strip testing more conservatively as a useful
tool for estimating community prevalence [3, 9, 10].
Interestingly, in most settings, there was some propor-
tion of ‘false positive’ (FP) reagent strip test resultsis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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S. haematobium through reference microscopy [4, 6].
Even after the administration of praziquantel, the preva-
lence of microhaematuria rarely goes to zero and au-
thors have suggested several explanations for this
observation. One suggestion is that some S. haemato-
bium infections were missed by microscopy. Especially
in low-prevalence settings, S. haematobium egg output
is generally low and thus hard to be detected by a single
filtration of only 10 ml of urine [2, 11]. Repeated urine
sampling and use of more sensitive diagnostic assays
might remedy this issue [6, 7, 11]. Another explanation
is that bladder lesions and associated microhaematuria
persisted longer than the actual excretion of eggs into
the bladder [12]. A third reason why some microhaema-
turia is unrelated to urogenital schistosomiasis is that re-
sidual menstrual blood or pregnancy in females results
in positive reagent strip results [13]. Fourth, it has been
noted that tests from different manufacturers performed
differently in their ability to detect microhaematuria. For
example, the Hemastix® (Bayer Diagnostics; Basingstoke,
United Kingdom) proved less sensitive than the Com-
bur9 Test® (Roche Diagnostics; Basel, Switzerland) for
microhaematuria and S. haematobium infection as con-
firmed by microscopy [3, 14]. Finally, S. haematobium
infection is not the only aetiology of microhaematuria
[15, 16].
The purpose of this study was to assess the diagnostic
accuracy of reagent strips for microhaematuria with par-
ticular consideration of settings characterised by low
levels of S. haematobium prevalence. We addressed
three specific research questions. First, does the level of
microhaematuria correspond to the level of S. haemato-
bium infection in low-prevalence settings? Second, is
microhaematuria – that seems unrelated to S. haemato-
bium – merely due to missed cases? Third, can micro-
haematuria be used as a proxy for S. haematobium in
low-prevalence (<20 %) areas or settings with very-low
prevalence that are targeted for elimination (<5 %)?Methods
Ethical considerations
The three study protocols from which original data were
obtained for the current analysis (two studies in Côte
d’Ivoire, one in Chad) were approved by the institutional
research commission of the Swiss Tropical and Public
Health Institute (Swiss TPH; Basel, Switzerland) and re-
ceived clearance from the ethics committees of Basel
(EKBB; reference nos. 377/09 and 64/13) and the na-
tional ethics committee in Côte d’Ivoire (reference no.
32-MSLS/CNERdkn and 1993 MSHP/CNER). In Chad,
research authorization including ethical approval was
granted by the ‘Direction Générale des ActivitésSanitaires’ in N’Djamena (reference no. 343/MSP/SE/
SG/DGAS/2013).
District, regional and local authorities, village chiefs,
study participants and parents/guardians of individuals
aged below 18 years were informed about the purpose,
procedures and potential risks and benefits of the study.
Information was provided in the national language
(French), as well as common languages spoken in southern
and northern Côte d’Ivoire (Baoulé, Dioula/Peulh/Fula and
Senoufo) and the Lake Chad area (Arab, Dioula/Peulh/Fula
and Kanembou). All authorities and camp/village chiefs
were asked for written or oral consent for the conduct of
the study in the respective administrative area. In Côte
d’Ivoire, written informed consent was obtained from all
participants and the parents/guardians of minors. In case of
illiteracy, consent was given in front of an impartial witness
of the participant’s choosing who signed in the name of the
participant. In Chad, informed consent was signed by the
camp leader in the presence of an impartial witness after
discussion within the group. Due to high illiteracy rates,
participating individuals consented orally. These consent
procedures had been approved by the respective ethics
committees.
Participation was voluntary and there were no further
obligations for those who withdrew from the study. All
results were coded and treated confidentially. At the end
of the studies, all individuals found with a Schistosoma
infection were offered a single 40 mg/kg oral dose of
praziquantel free of charge.
Data
Côte d’Ivoire
During the course of a relatively large study performed
in 2014/2015 in the Tchologo region in northern Côte
d’Ivoire [17], participants from 28 randomly selected vil-
lages, including one to two unofficial settlements in close
proximity to the villages, were asked to provide a urine
sample. Sample collection was performed throughout the
day with 47 % of all samples collected between 10 a.m.
and 2 p.m., 83 % before 4 p.m. and 98 % before 6 p.m.
Urine samples were transferred to nearby laboratories in
Korhogo and Ouangolodougou, where they were sub-
jected to reagent strip testing (Hemastix®, Bayer Diagnos-
tics; Basingstoke, United Kingdom) and the standard
urine filtration method. In brief, reagent strips were per-
formed according to the manufacturer’s instructions and
results recorded as negative, trace, 1+, 2+ and 3+. With
regard to the urine filtration method, one urine sample
was examined with a single filtration. In brief, 10 ml of a
vigorously shaken specimen were pressed through a
13 mm diameter Nytrel filter with a mesh size of 20 μm
(Sefar AG; Heiden, Switzerland), placed on a microscope
slide, stained with a drop of Lugol's iodine and then exam-
ined under a microscope systematically enumerating
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were performed by the same technician and laboratory as-
sistant. 15 % of the slides were subjected to quality con-
trol. In case of discrepancies between the two readings, all
slides of the respective day were read a second time.
Additionally, we re-examined data from a study con-
ducted in 2010 in Grand Moutcho in south Côte d’Ivoire
that assessed the dynamics of S. haematobium egg out-
put following oral administration of a single dose of
praziquantel (40 mg/kg). Details of this study have been
published elsewhere [18]. In brief, urine samples of two
consecutive days were collected from 124 children aged
7–15 years during a baseline survey. Each sample was
tested using urine filtration with Lugol’s iodine staining
and reagent strip tests (Combur-7-Test®, Roche Diagnos-
tics; Basel, Switzerland) for microhaematuria, proteinuria
and leukocyturia. All S. haematobium-positive children
(n = 90) were treated. Subsequently, single urine samples
were collected from all treated children on each school
day (four times per week) for the first 2 weeks and then
twice a week up to 8 weeks post-treatment. All samples
were subjected to urine filtration and reagent strip test-
ing for microhaematuria, proteinuria and leukocyturia
(Combur 7 Test®).
Chad
Urine filtration of 10 ml or whole urine samples from
single urine specimens (without Lugol’s iodine staining)
and reagent strip testing (Hemastix®, Bayer Diagnostics;
Basingstoke, United Kingdom) were likewise performed
in the Lake Chad area, where 19 randomly selected
groups of mobile pastoralists from four ethnic groups
were enrolled in 2013 and 2014. Participants were
followed up twice; 6 and 12 months after the baseline
survey. Participants found positive for schistosomiasis
with urine filtration and/or with a point-of-care cathodic
circulating antigen (POC-CCA) urine cassette test for
the detection of Schistosoma mansoni infection, were
treated with a single dose of praziquantel (40 mg/kg).
All parasitological tests in Chad were performed on the
spot in a mobile laboratory by one of the authors (HG)
with assistance from experienced laboratory technicians.
Published data from recent Cochrane systematic review
Relevant data from a recent Cochrane systematic review
entitled “Circulating antigen tests and urine reagent
strips for diagnosis of active schistosomiasis in endemic
areas” [4] were extracted and re-organised by prevalence
to put our data in the context of the extant literature.
Statistical analysis
Data were analysed using Stata/IC version 12.1 (Stata-
Corp; College Station, TX, United States of America). A
random effects logit regression was employed on ouroriginal data with village/camp included as random ef-
fect to calculate the relationship between microhaema-
turia and S. haematobium prevalence, the latter
confirmed by urine filtration. Reagent strips were read
qualitatively (positive or negative). Trace-positive re-
agent strips were considered as positive. Of note, distin-
guishing between reagent strip read-out intensities did
not change the results notably, except reducing the
sample size.
Data from the recent Cochrane systematic review were
entered as the number of ‘true positives’ (TP), FP, ‘false
negatives’ (FN) and ‘true negatives’ (TN), as reported in
the Cochrane systematic review. Subsequent percentages
were calculated from these numbers and compared to
our data. To examine test performance for different
prevalence levels, all baseline and follow-up survey re-
sults were grouped according to prevalence categories
(0–5 %, 5–10 %, 10–20 %, 20–50 % and 50–100 %).
Results
Study participants and prevalence
In the Tchologo region of northern Côte d’Ivoire, 8–33
individuals per village (including nearby Peulh camps)
were included in the study. Overall, there were 831 par-
ticipants and among them, 809 provided a urine sample.
Single reagent strip reading and urine filtration were
available from 805 and 802 of the participants, respect-
ively, and 801 participants (493 females and 308 males)
had complete data. The prevalence of S. haematobium
based on single urine filtration was 2.2 %, whereas a
positive reagent strip test result was noted in 19.5 % of
the participants.
In Grand Moutcho, south Côte d’Ivoire, 124 school-
aged children (62 females and 62 males) participated in
a baseline survey. The prevalence of S. haematobium
and microhaematuria was 74 % and 62 %, respectively at
day 1 of the baseline survey and 70 % and 66 %, respect-
ively at day 2 of the baseline. The overall prevalence of
S. haematobium and microhaematuria for both baseline
days combined was 79 % and 71 %, respectively [18].
In Chad, a total of 402 participants provided a urine
sample and 369 of them (181 females and 188 males)
were tested with reagent strips and urine filtration. 214
individuals (62.9 %) provided a subsequent sample for
the first follow-up and 75 (22.1 %) provided a sample for
the second follow-up. A total of 60 individuals were
treated with praziquantel at baseline as they had a posi-
tive test result (either urine filtration or POC-CCA for
S. mansoni) or because health personnel suggested treat-
ment based on clinical assessment. Urine filtration re-
vealed prevalence of S. haematobium of 7.9 % at
baseline, 2.7 % at the first and 2.6 % at the second
follow-up. Microhaematuria was found in 21.1 % at
baseline and in 12.7 % and 10.4 % at the first and second
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with light intensity infections (egg excretion <50 egg per
10 ml of urine) had a negative reagent strip test result
significantly more often (p < 0.005) than individuals with
heavy infection intensity (egg excretion ≥50 egg per
10 ml of urine).
Of note, the prevalence of S. mansoni, as assessed with
duplicate Kato-Katz thick smears from a single stool
sample in northern Côte d’Ivoire was 0.8 %. In Chad,
single Kato-Katz think smears and an ether-
concentration method revealed a prevalence of S. man-
soni of 0.3 %.
Performance of reagent strip testing compared to urine
filtration
In our studies, reagent strip testing resulted in reason-
able sensitivities of 61.1 % (north Côte d’Ivoire), 75.9 %
(Chad) and 87.8 % (south Côte d’Ivoire). SpecificitiesFig. 1 Flowchart of study participation, sample provision and diagnostic te
part and Grand Moutcho in the southern part) and one site in Chadwere somewhat higher; 81.5 % (north Côte d’Ivoire),
83.5 % (Chad) and 92.3 % (south Côte d’Ivoire).
A random effects logit regression between reagent
strip tests and urine filtration outcome with village in-
cluded as random effect, revealed an odds of having a
positive filtration when reagent strip testing was positive
of 7.4 (95 % confidence interval (CI): 2.3–23.8) in north-
ern Côte d’Ivoire, 86.0 (95 % CI: 18.0–410.8) in southern
Côte d’Ivoire and 20.7 (95 % CI: 7.5–57.3) in Chad. The
respective Kappa agreements between the filtration re-
sults and the reagent strip test results all showed nearly
perfect agreement; 0.81 (northern Côte d’Ivoire), 0.88
(southern Côte d’Ivoire) and 0.83 (Chad) [19].
The positive predictive value (PPV), which indicates
the likelihood (in %) of being infected with S. haemato-
bium if tested positive for microhaematuria, differed
greatly from one study to another (7.1 % in north Côte
d’Ivoire, 28.2 % in Lake Chad area and 97.7 % in southsts performed in two sites in Côte d’Ivoire (Tchologo in the northern
Table 1 Reagent strip test performance in the three study sites
Study TP FP FN TN Egg positive Microhaematuria Sensitivity Specificity PPV NPV
Côte d’Ivoire, Tchologo 11 145 7 638 2.2 % 19.5 % 61.1 % 81.5 % 7.1 % 98.9 %
Chad, baseline survey 22 56 7 284 7.9 % 21.1 % 75.9 % 83.5 % 28.2 % 97.6 %
Chad, first follow-up survey 4 24 2 190 2.7 % 12.7 % 66.7 % 88.8 % 14.3 % 99.0 %
Chad, second follow-up survey 1 7 1 68 2.6 % 10.4 % 50.0 % 90.7 % 12.5 % 98.6 %
Côte d’Ivoire, Grand Moutcho 86 2 12 24 79.0 % 71.0 % 87.8 % 92.3 % 97.7 % 66.7 %
FN false negative (negative with reagent strip, positive with filtration), FP false positive (positive with reagent strip, negative with filtration), NPV negative
predictive value, PPV positive predictive value, TN true negative (negative with both, reagent strip and filtration), TP true positive (positive with reagent strip
and filtration)
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lihood of not being infected with S. haematobium if
tested negative with reagent strip), on the other hand,
was very high in all of our surveys. A detailed descrip-
tion of test performance in each of the three study sites
including the follow-up surveys at Lake Chad are sum-
marised in Table 1. The model predicted odds for having
microhaematuria despite a negative urine filtration result
at baseline were 7.1 in northern Côte d’Ivoire, 28.2 in
the Chad setting and 79.0 in southern Côte d’Ivoire.
Test performance by prevalence
Data obtained in our studies and data from the
Cochrane systematic review showed that, regardless of
the setting, around 15–20 % of the subjects had micro-
haematuria whenever the prevalence of S. haematobium
was below 21 %. Above this prevalence level, microhae-
maturia increased in parallel to S. haematobium (Fig. 2).
While sensitivity and specificity were relatively stable
over various prevalence levels, PPV and NPV are inher-
ently dependent on prevalence (Figs. 3 and 4). However,
the percentage of microhaematuria seemingly unrelated
to S. haematobium was stable over different prevalence
ranges when taken into account that it will be hidden
for higher prevalences.
Treatment prior to testing did not substantially alter
the picture and seemingly unrelated microhaematuria,Fig. 2 Average microhaematuria over S. haematobium prevalence from all su
to data from our three surveys (two in Côte d’Ivoire, one in Chad)although slightly less, showed the same pattern across
prevalence ranges (Fig. 5). When the dynamics of micro-
haematuria was examined over an 8-week period post-
treatment for children who tested positive for S. haema-
tobium at baseline and were given a single 40 mg/kg oral
dose of praziquantel, it was found that, while the preva-
lence of microhaematuria drops about similarly as the
egg output over time, the level of microhaematuria
seemingly unrelated to S. haematobium egg output
quickly reached the same overall background level as
found in other studies. The model-predicted odds for
having microhaematuria despite a negative filtration re-
sult, reached a stable level after the first week post-
treatment (Fig. 6).
Furthermore, our data indicate that this seemingly un-
related microhaematuria is mostly independent of gen-
der. Although females consistently showed slightly
higher levels of microhaematuria seemingly unrelated to
S. haematobium than males in our studies from north-
ern Côte d’Ivoire and Chad, this gender difference was
only marginal over all age groups with the exception of
females and males aged 45 years and above (Fig. 7).
Theoretical assessment of the likelihood of missed cases
as explanation for seemingly unrelated microhaematuria
If we assume that all cases of “unrelated” microhaema-
turia can be explained by true S. haematobium casesrveys as scatter plot and box plot. Light-orange lines in the box plot refer
Fig. 3 Test parameters (arithmetic mean of all studies) at different prevalence categories before and after treatment. Each follow-up survey in our
studies was counted as a separate survey
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prevalence of “unrelated” microhaematuria could be cal-
culated as follows:
Expected true prevalence of S. haematobium times the
probability to miss a remaining infection.
One way to control for the true prevalence is to
consider post-treatment studies only. Yet, although it
reduces infection intensity, treatment with praziquan-
tel does not always completely cure an infected
individual. Hence, the following assumptions were
considered:
① 18 % of treated individuals are not fully cured [20];
② 20 % of low intensity S. haematobium cases are
missed by urine filtration (note, the 20 % difference in
case-detection stems from a single compared to tripli-
cate urine filtrations in a lightly infected study group)
[11]; and
③ 5.7 % S. haematobium cases present without
microhaematuria (note, arithmetic mean ofFig. 4 Positive and negative predictive values over S. haematobium prevalencS. haematobium infections without microhaematuria
from all post-treatment studies from the Cochrane sys-
tematic review and our own data, excluding one study
of the Cochrane review with an exceptionally high
number of S. haematobium cases without
microhaematuria).
The expected prevalence of FP reagent strips would
consist of the uncured S. haematobium cases (present-
ing with microhaematuria) missed by urine filtration.
Hence: ① +② + (1 - ③) = 0.18 * 0.2 * (1–0.057) = 3.4 %.
The remaining FP reagent strip results cannot rationally
be attributed to missed cases of S. haematobium.
If we assume that half of the treatments do not com-
pletely cure S. haematobium infections, the same rationale
would lead to an expected 9.4 % (0.2 * 0.5 * (1–0.057)) of
seemingly unrelated microhaematuria which could be ex-
plained by missed S. haematobium cases. Re-infection can
of course increase the prevalence of S. haematobium after
treatments. The level of re-infection in the includede.
Fig. 5 Microhaematuria not associated with S. haematobium,
stratified by S. haematobium prevalence in the study. Solid regression
line, all studies; dashed regression line studies post-treatment
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bers to a large extent.
Discussion
The current comparison of findings of S. haematobium
eggs in urine and microhaematuria detected by reagent
strips confirmed that the usefulness of microhaematuria
as a proxy for estimating community prevalence of uro-
genital schistosomiasis is influenced by the overall preva-
lence of S. haematobium [3, 4, 6, 11, 21, 22]. The Kappa
agreement between the two tests revealed very good
agreement (>0.80). Moreover, the sensitivity and specifi-
city of microhaematuria have repeatedly been found to
be high enough for the reagent strip testing to be a valid
diagnostic tool for S. haematobium at the community
level. These parameters are considerably influenced byFig. 6 Dynamics of microhaematuria and model-predicted odds of microh
period post-treatment of all positive participantsthe association of S. haematobium infection with micro-
haematuria (94.3 %). However, PPV was very low in low-
prevalence settings indicating that either large fractions
of microhaematuria in such settings are unrelated to
schistosomiasis or that the true prevalence of S. haema-
tobium in these settings is grossly underestimated. NPV
and PPV are well known to be prevalence-dependent
with lower PPV and higher NPV the lower the preva-
lence of the disease in a given setting [23, 24]. In this
sense our findings on the NPV and PPV are not novel,
yet, they imply that a positive reagent strip test would
not necessarily relate to a positive S. haematobium result
in very-low prevalence settings.
Our findings have several implications that are offered
for discussion. First, regardless of the study settings,
there seems to be some level of “background microhae-
maturia”, which is, at first glance, not directly related to
S. haematobium infection. The average level of this
seemingly unrelated microhaematuria was around
13 % across settings and reported S. haematobium
prevalences. The observation that background
microhaematuria tends to decline with higher preva-
lence of S. haematobium (visualized in Fig. 5) can
be explained by the increasing probability to be in-
fected with S. haematobium, which will hide any un-
related microhaematuria either because it is being
attributed to schistosomiasis or because it co-occurs
with S. haematobium-induced microhaematuria.
Some authors have argued that most of this
background microhaematuria is due to undetected
S. haematobium explained by the lack of sensitivity of
widely used diagnostic tools [25, 26]. However, data
from studies performed after praziquantel administra-
tion challenge this hypothesis. Indeed, after prazi-
quantel administration, the number of seemingly
unrelated microhaematuria attributable to missedaematuria seemingly unrelated to S. haematobium over an 8-week
Fig. 7 Seemingly unrelated microhaematuria, S. haematobium prevalence with and without associated microhaematuria and overall prevalence of
microhaematuria by sex and age-group in northern Côte d’Ivoire and in the baseline survey in Chad
Krauth et al. Parasites & Vectors  (2015) 8:584 Page 8 of 10S. haematobium cases consist of individuals for whom
treatment failed to completely clear infection (or
perhaps explained by the presence of immature
S. haematobium flukes that are only marginally af-
fected by praziquantel or the occurrence of rapid re-
infection). If 20 % of S. haematobium cases are
missed by urine filtration [11] and 18 % of positive
S. haematobium cases treated with praziquantel are
not fully cured [20] and 5.7 % of S. haematobium in-
fections present without microhaematuria, only 3.4 %
(0.18 * 0.2 * (1–0.057)) of seemingly unrelated micro-
haematuria cases would be attributable to missed
cases in post-treatment studies. The remaining unre-
lated microhaematuria of, say at least 10 %, would re-
main unexplained and further studies are warranted
to assess the cause of this microhaematuria. Potential
aetiologies include bladder-stones or urinary tract in-
fections and sickle cell disease as well as persistent
bladder lesions from cured S. haematobium infections
[15, 27–29]. Truly FP reagent strip results have also
been reported, and are thought to be caused by the
presence of semen in urine [30]. However, some stud-
ies suggest that cure rates of S. haematobium infec-
tions after praziquantel administration vary greatly
depending on the study and the diagnostic effort and
can be as low as 50 % [31, 32] which would indicate
that the majority of the background microhaematuria
that we found throughout settings would indeed be
explained by S. haematobium infections missed by
urine filtration. If this assessment holds, it would
mean that there is a persisting S. haematobium preva-
lence of around 10–15 % in settings which were char-
acterised to have lower prevalences. In turn, this
would change the current picture about schistosomia-
sis burden of disease as well as the evaluation of the
success of schistosomiasis control and elimination
programmes. Indeed, a recent study on a promisinghigh-sensitivity diagnostic tool based on the detection
of a circulating anodic antigen (CAA) did find a
prevalence of 13.3 % of S. haematobium with the
antigen test when urine filtration found a prevalence
of only 3.3 % and reagent strip testing found a preva-
lence of 4.1 % [33].
Due to the lack of a ‘gold’ standard in S. haematobium
diagnosis, it cannot be ascertained 100 % whether this
background haematuria results from missed S. haemato-
bium cases or from alternative causes of microhaema-
turia. The level of seemingly unrelated microhaematuria
did not differ much between males and females for dif-
ferent age groups, excluding the explanation of unrelated
microhaematuria caused by pregnancy or menstruation.
If the observed background haematuria is due to differ-
ent aetiologies, such as bladder-stones or urinary tract
infections [15, 27, 28], it follows that individual
treatment-decisions targeting S. haematobium should
not merely be based on reagent strip results, particularly
in low-prevalence settings.
In either case, researchers, health care personnel and
disease control managers need to be aware that in set-
tings with S. haematobium prevalence below 20 %, espe-
cially in settings targeted for elimination, a positive
reagent strip test should always be followed up with
urine filtration or better with other, more sensitive, diag-
nostic assays. Moreover, in view of the likelihood to miss
an infection, which is, in addition, higher in low-
intensity infections, and the fact that egg output shows a
considerable day-to-day fluctuation [3, 34, 35], the
follow-up diagnosis should contain multiple samples
over consecutive days.
Taken together, while reagent strip testing remains a
valid tool for rapid assessment of community prevalence
of S. haematobium [3, 9, 10] or even for individual diag-
nosis [2, 4, 7], one has to consider the epidemiological
setting in which the test is executed as well as the goals
Krauth et al. Parasites & Vectors  (2015) 8:584 Page 9 of 10of a schistosomiasis control and elimination programme
or the specific research questions.
Praziquantel is a safe and efficacious drug that is rec-
ommended for preventive chemotherapy against schisto-
somiasis [36, 37]. As preventive chemotherapy is
escalating and schistosomiasis elimination is the new
goal [38, 39], settings characterised by very-low preva-
lence and intensity of Schistosoma infection are becom-
ing the norm rather than the exception and this has
important ramifications for the use of diagnostic assays.
Conclusion
Irrespective of the true cause of the persisting back-
ground prevalence of microhaematuria—be it missed
S. haematobium cases or alternate causes for micro-
haematuria—the overwhelming implication of our
findings and those of other researchers, is that there
is a pressing need for more accurate diagnostic tools
(higher sensitivity and higher specificity) if we indeed
want to aim for elimination of schistosomiasis in se-
lected settings [26, 33, 36, 38]. New research and
funding efforts should target the well-known weak-
nesses of currently available diagnostic assays for uro-
genital schistosomiasis.
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